Is Mounjaro Good for Your Heart? What Studies Show

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, appears to benefit the heart across several measures, though the picture is more nuanced than a simple thumbs-up. The largest dedicated cardiovascular trial, SURPASS-CVOT, found that tirzepatide reduced a broad composite of heart attacks, strokes, heart failure hospitalizations, kidney events, and death by about 16% compared with dulaglutide, a drug already known to protect the heart.¹ Separate trials in heart failure patients, real-world database studies, and research into how the drug reshapes blood pressure, lipids, and inflammation all add layers to that headline finding.

What the Largest Cardiovascular Trial Found

SURPASS-CVOT was designed specifically to test whether tirzepatide protects the heart in people with type 2 diabetes who already have atherosclerotic cardiovascular disease. It enrolled over 13,000 participants and compared weekly tirzepatide injections (up to 15 mg) against weekly dulaglutide (1.5 mg) for a median of about four years.² That comparison matters: dulaglutide is not a placebo. It is itself a GLP-1 drug that already demonstrated cardiovascular benefit in prior trials. Beating it, or even matching it, is a high bar.

On the primary three-component outcome of cardiovascular death, heart attack, or stroke (often called MACE), tirzepatide met noninferiority but did not achieve clear-cut superiority over dulaglutide. The hazard ratio was 0.92, with the confidence interval just barely crossing 1.0.³ However, a broader six-component composite that added coronary revascularization, heart failure events, and kidney endpoints did show clear superiority, with a 16% risk reduction.¹ Deaths from any cause dropped as well: about 8.6% of tirzepatide-treated patients died over the trial period compared with 10.2% on dulaglutide.

Because the comparison arm was an active drug rather than a sugar pill, researchers estimated what the results would look like against a hypothetical placebo. That analysis suggested tirzepatide might reduce MACE by roughly 28% compared with no incretin therapy at all.³ That imputed number is an estimate, not a direct measurement, but it helps place tirzepatide’s effect in context alongside semaglutide and liraglutide trials that used actual placebo arms.

Heart Failure With Preserved Ejection Fraction

One of the more striking results for tirzepatide comes from a different patient group entirely: people with heart failure with preserved ejection fraction (HFpEF) and obesity. This is a form of heart failure where the heart pumps normally but cannot relax and fill properly, often worsened by excess weight pressing on the heart and increasing blood volume. It has historically been one of the most frustrating conditions in cardiology because few drugs have shown convincing benefit.

The SUMMIT trial randomized about 730 patients with HFpEF and obesity to tirzepatide or placebo. Over 52 weeks, the composite of cardiovascular death or worsening heart failure events occurred in about 10% of tirzepatide-treated patients compared with roughly 15% on placebo, a 38% relative risk reduction.⁴ The benefit was driven almost entirely by fewer worsening heart failure events (hospitalizations and urgent visits), not by a reduction in cardiovascular death, which was too rare in both groups to draw conclusions from.

Beyond event counts, the patients on tirzepatide felt meaningfully better. Their heart failure symptom scores improved by about 7 points more than the placebo group on a standard quality-of-life questionnaire, and they walked roughly 18 meters farther in a 6-minute walk test.⁵ They also shifted toward less severe heart failure classifications and needed fewer heart failure medications over the study period. For a condition where patients often just get slowly worse, that trajectory is unusual.

How It Affects Blood Pressure

High blood pressure is the single biggest modifiable driver of heart disease, so any drug that lowers it consistently earns attention. Tirzepatide does. Across the SURPASS diabetes trials, systolic blood pressure dropped by roughly 3 to 13 mmHg depending on the dose and the comparison group.⁶ In the SURMOUNT-1 obesity trial, which studied people without diabetes, the net reduction was about 7 mmHg systolic and 4 mmHg diastolic versus placebo by 72 weeks. Participants on any tirzepatide dose were substantially more likely to have normal blood pressure by the end of the trial: 58% versus 35% on placebo.⁷

A mediation analysis from that same study estimated that weight loss explained about two-thirds of the blood pressure drop, which means roughly a third of the reduction comes from something else the drug is doing.⁷ In the SUMMIT trial of heart failure patients, blood pressure fell by about 5 mmHg systolic beyond what the placebo group experienced, accompanied by a meaningful reduction in estimated blood volume.⁸ For heart failure patients specifically, reducing how much fluid the body holds is a central goal of treatment, and tirzepatide appears to contribute to that without being a traditional diuretic.

Lipids, Inflammation, and the Arteries Themselves

Cardiovascular risk is not just about blood pressure. The types and sizes of cholesterol particles in your blood, the level of background inflammation, and the health of artery walls all play roles. Tirzepatide appears to improve each of these, at least to some degree.

In a detailed lipid analysis from an early trial, tirzepatide at the highest dose cut triglycerides by about 41% compared with placebo and reduced apoB (a marker of the number of particles that can deposit cholesterol in artery walls) by roughly 17%.⁹ It also reduced small, dense LDL particles, the type most associated with plaque buildup, and improved a composite insulin resistance score. These effects were dose-dependent, with higher tirzepatide doses producing bigger shifts.

On the inflammation front, tirzepatide lowered C-reactive protein (CRP), a widely used marker of systemic inflammation, by about 37% in the SUMMIT heart failure trial.⁸ That same analysis showed reductions in troponin T, a marker of low-grade heart muscle injury. In animal studies, tirzepatide reduced the stickiness of blood vessel walls to immune cells and blunted a key inflammatory signaling pathway, which may help explain how it slows atherosclerotic plaque development beyond simply improving metabolic numbers.¹⁰ These are mouse studies, so direct translation to humans is uncertain, but they do provide a plausible biological story for why the clinical benefits might extend beyond what weight loss alone would predict.

Fat Around the Heart

Obesity-related heart disease is not only about subcutaneous fat you can see. Fat that accumulates directly around the heart, called paracardiac or epicardial adipose tissue, is increasingly recognized as an independent risk factor. It sits right next to heart muscle and coronary arteries, and it secretes inflammatory molecules locally. In the SUMMIT trial, cardiac MRI showed that tirzepatide reduced paracardiac fat by about 45 milliliters more than placebo.¹¹ It also reduced the mass of the left ventricle, the heart’s main pumping chamber, which tends to thicken as it works harder under the stress of obesity and high blood pressure.

A follow-up analysis found that these reductions in paracardiac fat and ventricular mass were similar regardless of whether patients had type 2 diabetes.¹² That is worth noting because it suggests the cardiac remodeling benefit is tied more to weight and fat loss than to glucose control specifically.

The Heart Rate Question

Not every cardiovascular signal from tirzepatide points in a favorable direction. Like other GLP-1-based drugs, it increases resting heart rate. A meta-analysis pooling data from multiple tirzepatide trials found an average increase of about 2 beats per minute compared with combined controls, and the effect was dose-dependent: the 15 mg dose raised heart rate by roughly 3 beats per minute more than the 5 mg dose.¹³ At the highest dose, heart rate rose by about 3 beats per minute more than even other GLP-1 drugs.

An increase of 2 to 3 beats per minute is modest, and for most people it is unlikely to be clinically meaningful. But in large populations, even small persistent heart rate elevations can theoretically contribute to adverse outcomes over years. Whether this effect matters in practice is hard to disentangle from the simultaneous improvements in blood pressure, weight, lipids, and inflammation, which all push risk in the opposite direction. In the SURPASS-CVOT trial, this heart rate signal did not translate into higher rates of arrhythmia or sudden cardiac death, but it remains something researchers are watching.

Kidney Protection and Why It Matters for the Heart

Heart disease and kidney disease feed each other in a vicious cycle. Damaged kidneys raise blood pressure, retain fluid, and accelerate atherosclerosis; a failing heart starves the kidneys of blood flow. Any drug that protects one organ often helps the other. Tirzepatide shows notable kidney-protective effects.

In the SURPASS-4 trial, which compared tirzepatide to insulin glargine in people with type 2 diabetes at high cardiovascular risk, a composite kidney endpoint (including kidney function decline, kidney failure, and new-onset heavy protein leakage in the urine) was reduced by about 41% with tirzepatide.¹⁴ Most of that benefit came from preventing new macroalbuminuria, an early warning sign that the kidneys’ filtering units are breaking down. Kidney function itself declined more slowly on tirzepatide: the annual rate of filtration loss was about 1.4 units per year on tirzepatide compared with 3.6 on insulin glargine.

In SURPASS-CVOT, the kidney endpoint also favored tirzepatide over dulaglutide, with about a 21% reduction in composite kidney outcomes.¹ A broader scoping review confirmed that tirzepatide consistently reduced albuminuria and slowed kidney function decline across multiple studies.¹⁵ For patients with both heart disease and early kidney trouble, this dual protection is a meaningful advantage.

How Tirzepatide Compares With Semaglutide

Many people weighing Mounjaro against Ozempic or Wegovy (all brand names for semaglutide) want to know which is better for the heart. The honest answer: the data are mixed, and the comparison is complicated by different trial designs.

A real-world observational study called STEER, which followed people with overweight or obesity (not necessarily diabetes), found that semaglutide was associated with a lower risk of major cardiovascular events than tirzepatide, with about a 29% reduction in three-component MACE.¹⁶ However, a separate target trial emulation using a different database found the opposite: tirzepatide was associated with a lower risk of heart failure, atrial fibrillation, and heart attack compared with semaglutide, with risk ratios of roughly 0.60 to 0.82 depending on the outcome and the population.¹⁷

A propensity-matched simulation found that semaglutide showed slightly more pronounced cardiovascular protection in terms of composite events, while tirzepatide delivered stronger metabolic improvements like greater weight loss and HbA1c reduction.¹⁸ Meanwhile, a large real-world study published in Nature Medicine that directly compared tirzepatide and semaglutide in clinical practice found essentially no difference: the one-year risk of the primary cardiovascular endpoint was 1.3% for both drugs.¹⁹

The conflicting results likely reflect differences in study populations, follow-up duration, outcome definitions, and the inherent limitations of observational data. No head-to-head randomized trial has compared the two drugs purely on cardiovascular endpoints. For now, the safest conclusion is that both drugs offer meaningful cardiovascular benefit, and neither has clearly pulled ahead of the other on hard cardiac outcomes.

Real-World Evidence Beyond Clinical Trials

Clinical trials enroll carefully selected patients who are closely monitored, which is both their strength and their limitation. Real-world studies, which analyze insurance claims and electronic health records, fill in the picture of how drugs perform in typical clinical practice with messier, more diverse populations.

A large population-based cohort study compared tirzepatide with sitagliptin, an older diabetes drug with no established cardiovascular benefit. Over an average on-treatment follow-up of about six months, the risk of major cardiovascular events was roughly 2.9% with tirzepatide and 4.4% with sitagliptin, a difference corresponding to a 32% relative risk reduction. The separation between the two groups appeared within the first three months and continued to widen.²⁰ The number needed to treat to prevent one major cardiovascular event at one year was 70, which places tirzepatide in a similar neighborhood to established cardiovascular drugs like statins and SGLT2 inhibitors for high-risk populations.

When individual components were examined, heart attack risk was reduced by about a third, and all-cause mortality was cut nearly in half. The stroke signal was weaker and did not reach statistical significance in this study.²⁰ These findings are consistent with the SURPASS-CVOT trial, where the stroke reduction was also the smallest and most uncertain of the individual event types.

What the GIP Receptor Adds

What makes tirzepatide different from semaglutide or liraglutide at the molecular level is that it activates two gut hormone receptors rather than one. In addition to the GLP-1 receptor that all drugs in this class target, tirzepatide also switches on the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP’s role in the body is complex and not fully understood. One of its known functions is promoting triglyceride storage in fat tissue, not just through its effect on insulin but through direct interactions with fat-tissue blood vessels and GIP receptors on fat cells.²¹

Paradoxically, this might be helpful. By steering triglycerides into subcutaneous fat (the relatively harmless kind under your skin) rather than letting them circulate or deposit in visceral and organ fat, GIP activation could reduce the metabolically toxic fat burden around the heart, liver, and kidneys. The SUMMIT imaging substudy supports this idea, showing large reductions in paracardiac fat. Whether GIP receptor activation contributes directly to cardiovascular protection or simply amplifies the benefits of GLP-1 signaling and weight loss remains an open question, and one that researchers are actively trying to untangle.

Cost and Access as a Practical Barrier

Even a drug with strong cardiovascular evidence means little if patients cannot afford it or cannot get coverage. Tirzepatide currently carries a list price that puts it out of reach for many without insurance coverage, and insurers have been slow to cover incretin-based therapies specifically for cardiovascular benefit rather than for diabetes or weight management. A cost-effectiveness analysis modeled the lifetime health effects and costs of tirzepatide and other anti-obesity medications against lifestyle modification alone, framing the economic question, but the real-world answer depends heavily on insurance formularies, negotiated prices, and whether cardiovascular indications expand coverage criteria.²²

For heart failure specifically, a separate cost-effectiveness model built on SUMMIT trial data evaluated whether tirzepatide for HFpEF with obesity would meet standard value thresholds in the U.S. healthcare system.²³ Mounjaro does not currently carry an FDA-approved indication for heart failure or cardiovascular risk reduction, which means prescribing it for those reasons may require off-label use and can complicate reimbursement. The cardiovascular evidence is building faster than the regulatory and insurance landscape is adapting to it.